Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
GEP-NET
Interventions
DRUG

nanoliposomal irinotecan plus carboplatin

"Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= \[(140-age) x weight x 0.85 (if female)\] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria."

Trial Locations (6)

Unknown

Chang-Gung Memorial Hospital, Kaohsiung, Kaohsiung City

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Chang Gung Memorial Hospital (Lin-Kou),, Linkou District

China Medical University Hospital, Taichung

National Cheng-Kung University Hospital, Tainan City

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER